On this page
The editorial assessment
The strongest purchase fact is the stated protocol total. Treat the monthly label as a separate presentation requiring clarification, and keep the source record distinct from an assessment of clinical effectiveness.
- Published offering
- A dedicated BPC-157 injectable page; proposed pharmacy and preparation require confirmation.
- Starting price
- $297 ten-week protocol, with a separate $99/month headline.
- Billing & renewal
- Read the selected product’s purchase period and renewal terms in the review.
- Verification scope
- Exact pharmacy assignment, individual licensure and dispensed-product quality not independently verified.
What is documented
- Dedicated product entry names the proposed preparation.
- A specific purchase period and total are published.
What needs an answer
- A public listing does not establish a clinical outcome or personal eligibility.
- The retrieved no-prescription payment policy needs a written answer.
Partner link. We may earn a commission.
The duration belongs in the record
A price comparison becomes misleading when the period is dropped. The Live Vital entry describes a ten-week protocol, not an established calendar-month refill. Record the purchase as shown and ask for a written explanation of any later charge. Do not convert the headline into a recurring annual total without an actual renewal schedule.
Separate the listing from the evidence
A provider product page records what a business proposes to supply. It is not a controlled study or a verification of a dispensed lot. Ask for the exact formulation and pharmacy assignment, then assess the relevant human evidence independently. A source-led review should leave those different evidentiary jobs visible.
An unanswered refund question remains unanswered
The retrieved policy does not resolve payment and refunds when no prescription is issued. A reader should ask for that answer before checkout, not assume a protection from another provider’s policy. The current review is limited to published information and does not report an enrollment or personal treatment experience.
A second record makes the contrast useful
Compare the PeptidesRx review for a different package and included-service description. The cost planner can then use the actual totals and periods from both records. The retrospective knee-report guide provides a separate example of why a patient report should not be upgraded into proof about every current BPC-157 prescription.
On the record
The documents supporting this report.
- Live Vital: dedicated product recordCompany website
- Live Vital: published refund policyCompany website
- Live Vital: state availabilityCompany website